0.038
0.00 (-2.56%)
| Penutupan Terdahulu | 0.039 |
| Buka | 0.040 |
| Jumlah Dagangan | 496,374 |
| Purata Dagangan (3B) | 3,846,365 |
| Modal Pasaran | 48,503,956 |
| Harga / Buku (P/B) | 9.54 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -349.02% |
| EPS Cair (TTM) | -0.040 |
| Nisbah Semasa (MRQ) | 3.87 |
| Aliran Tunai Operasi (OCF TTM) | -7.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.85 M |
| Pulangan Atas Aset (ROA TTM) | -367.10% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | TRYPTAMINE FPO [TYP] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.38 |
|
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 25.87% |
| % Dimiliki oleh Institusi | 0.82% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |